Report projects breast cancer drug sales to exceed $1 billion
WALTHAM, Mass. An investigational drug for treating breast cancer will garner sales of more than $1 billion in many developed countries by the end of the decade, according to a new report by market research firm Decision Resources.
According to the report, titled “Breast Cancer,” BSI-201 will have $1.7 billion in sales by 2018 in the United States, the United Kingdom, France, Germany, Spain, Italy and Japan. The report said the drug was expected to take “significant” market share from Avastin (bevacizumab), made by Roche, Genentech — now a part of Roche — and Chugai after its launch in 2012, in the United States and Europe, and its 2014 launch in Japan. The drug belongs to a nascent class known as PARP inhibitors, which also includes AstraZeneca’s olaparib and Pfizer’s AG-014699.
“Interviewed thought leaders are very optimistic about the PARP inhibitors and, in particular, about BSI-201’s potential in the triple negative breast cancer setting,” Decision Resources analyst Niamh Murphy said in a statement.
Alliance Health Networks forms healthcare advisory board
SALT LAKE CITY Alliance Health Networks, which is building a universe of social health networks focused on such specific health conditions as diabetes, has formed a healthcare advisory board. Among the founding members: pharmacy industry veteran Gordon Barker.
According to Alliance Health’s CEO, Stead Burwell, the advisory board is designed to provide Alliance Health executive management and its board of directors with industry insights, feedback and strategic counsel in support of its efforts to build online social health networks that bring together patients, caregivers and industry participants.
Alliance Health’s first social health network DiabeticConnect.com, has attracted the largest online population of people living with or treating diabetes, according to the company.
Barker has a nearly 40-year career in the pharmacy industry that includes 30 years with Thrifty PayLess Drug Stores, now Rite Aid. He started there as a pharmacist and eventually became president and CEO. He then served as CEO of Snyder Drug from 2005 through early 2009. In addition, Barker served as chairman of the board of the Juvenile Diabetes Research Found and currently serves on its board of chancellors.
Additional members of the advisory board include McKesson veteran, Richard Hawkins; and Robert Johnson, former chairman and CEO of PCS Health Systems, which is now part of CVS Caremark.
Inhaled CF antibiotic receives FDA approval
BETHESDA, Md. The Food and Drug Administration has approved the first inhaled antibiotic for cystic fibrosis in more than a decade, according to a cystic fibrosis advocacy organization.
The Cystic Fibrosis Foundation announced the FDA’s approval of Cayston (aztreonam), developed by Gilead Sciences. The organization invested $1 million to help development of the drug.
“The approval of Cayston demonstrates that our drug-development model is working and making a real difference in the lives of people with cystic fibrosis,” Cystic Fibrosis Foundation president and CEO Robert Beall said in a statement. “We are delighted to have a new antibiotic in the arsenal to help fight the life-threatening infections associated with this disease, as we continue to push forward with other therapies that address the underlying cause of CF.”